Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfredo Addeo

Showing results (51-60 of 224) with videos related to

Pageof 23
Sort By:
Clinical Medicine Insights. Oncology|July 26, 2023
Pleural Mesothelioma in the Era of ImmunotherapyMathieu Chevallier, Floryane Kim, Alex Friedlaender, et al.
Current Treatment Options in Oncology|September 5, 2019
Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLCAlex Friedlaender, Giuseppe Banna, Sandip Patel, et al.
Future Oncology (London, England)|October 23, 2024
Rates of febrile neutropenia and its causes in the real worldMaxime Borgeaud, Simona Perano, Alfredo Addeo, et al.
Cancer Journal (Sudbury, Mass.)|November 16, 2022
Antibody Drug Conjugates in Lung CancerGeoffrey Merle, Alex Friedlaender, Aakash Desai, et al.
JAMA Oncology|October 25, 2019
Tumor Mutation Burden-From Doubts to Concerns-In ReplyAlfredo Addeo, Giuseppe L Banna, Glen J Weiss
JAMA Oncology|May 31, 2019
Tumor Mutation Burden-From Hopes to DoubtsAlfredo Addeo, Giuseppe L Banna, Glen J Weiss
Ecancermedicalscience|January 26, 2019
Learning from the past to design better trials in second-line treatment for mesothelioma patientsAlfredo Addeo, Giuseppe Luigi Banna, Pierre-Yves Dietrich
Cancer Genomics & Proteomics|August 30, 2020
Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung CancerMathieu Chevallier, Petros Tsantoulis, Alfredo Addeo, et al.
Cancer Genomics & Proteomics|October 30, 2019
The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre ExperienceJavier Torralvo, Alex Friedlaender, Verane Achard, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 11, 2016
Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study?Vittorio Fusco, Alberto Bedogni, Alfredo Addeo, et al.
Pageof 23

Showing results (51-60 of 224) with videos related to

Sort By:
Pageof 23
Clinical Medicine Insights. Oncology|July 26, 2023
Pleural Mesothelioma in the Era of ImmunotherapyMathieu Chevallier, Floryane Kim, Alex Friedlaender, et al.
Current Treatment Options in Oncology|September 5, 2019
Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLCAlex Friedlaender, Giuseppe Banna, Sandip Patel, et al.
Future Oncology (London, England)|October 23, 2024
Rates of febrile neutropenia and its causes in the real worldMaxime Borgeaud, Simona Perano, Alfredo Addeo, et al.
Cancer Journal (Sudbury, Mass.)|November 16, 2022
Antibody Drug Conjugates in Lung CancerGeoffrey Merle, Alex Friedlaender, Aakash Desai, et al.
JAMA Oncology|October 25, 2019
Tumor Mutation Burden-From Doubts to Concerns-In ReplyAlfredo Addeo, Giuseppe L Banna, Glen J Weiss
JAMA Oncology|May 31, 2019
Tumor Mutation Burden-From Hopes to DoubtsAlfredo Addeo, Giuseppe L Banna, Glen J Weiss
Ecancermedicalscience|January 26, 2019
Learning from the past to design better trials in second-line treatment for mesothelioma patientsAlfredo Addeo, Giuseppe Luigi Banna, Pierre-Yves Dietrich
Cancer Genomics & Proteomics|August 30, 2020
Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung CancerMathieu Chevallier, Petros Tsantoulis, Alfredo Addeo, et al.
Cancer Genomics & Proteomics|October 30, 2019
The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre ExperienceJavier Torralvo, Alex Friedlaender, Verane Achard, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 11, 2016
Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study?Vittorio Fusco, Alberto Bedogni, Alfredo Addeo, et al.
Pageof 23